Yini Alatan

Dr. Yini Alatan

Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, Liaoning, China
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
PYPeiling Yu
Peiling Yu
WCWeixing Chen
Weixing Chen
NLNan Liu
Nan Liu
YYYang Yu
Yang Yu
HGHongyu Guo
Hongyu Guo
YMYuan Miao
Yuan Miao
PURPOSE: Accurately identifying gene mutations in lung cancer is crucial for treatment, while molecular diagnostic methods are time-consuming and complex. This study aims to develop an advanced deep learning model to address this issue. METHODS: In this study, the ResNeXt101 model framework was established to predict the gene mutation status in lung adenocarcinoma. The model was trained and validated using data from two cohorts: cohort 1, comprising 144 patients from the First Affiliated Hospital of China Medical University, and cohort 2, which includes 69 patients from the The Cancer Genome Atlas-Lung Adenocarcinoma public database. The model was trained and validated on the two data sets, respectively, and they served as external test sets for each other to further verify the performance of the model. Additionally, we tested the trained model on a metastatic cancer data set, which included metastases to organs outside the lungs. The performance of the model was evaluated using the AUC, accuracy, precision, recall, and F1 score. RESULTS: In cohort 1, the model achieved an AUC ranging from 0.93 to 1. In the external test on cohort 2, it performed well in predicting five of the six genes (AUC = 0.85-1). When tested on the metastatic cancer data set, it successfully predicted mutations of three of the six genes (AUC = 0.72-0.80). CONCLUSION: The artificial intelligence model developed in this study has a high accuracy in predicting gene mutations in lung adenocarcinoma, which is conducive to improving the management of patients with lung adenocarcinoma and promoting precision medicine.

18 October 2026 in Life
Verified
Journal Article
Open access
PDF file
YAYini Alatan
Yini Alatan
FZFenghao Zheng
Fenghao Zheng
PYPeiling Yu
Peiling Yu
YYYinan Yuan
Yinan Yuan
HGHongyu Guo
Hongyu Guo
YMYuan Miao
Yuan Miao
Plasmablastic/anaplastic plasma cell neoplasms (P/APC-N) and plasmablastic lymphoma (PBL) represent two categories of highly aggressive hematolymphoid malignancies. Their distinction is clinically important because they are classified and treated within different disease frameworks, yet no single morphologic, immunophenotypic, viral, cytogenetic, or molecular finding reliably resolves all cases. The proposed approach begins with the clinical and systemic context, including a pre-existing plasma cell neoplasm, marrow and serum findings, myeloma-defining events, immune status, and disease distribution. Morphologic assessment is followed by a panel evaluating plasma-cell differentiation, conventional B-cell markers, light-chain restriction, proliferative activity, and tumor-cell Epstein–Barr virus-encoded RNA (EBER) by in situ hybridization. Evidence of an established plasma cell neoplasm and a coherent myeloma-associated genomic background favor the relevant plasma cell neoplasm subtype, whereas tumor-cell EBER positivity in a compatible context supports PBL but is not specific. MYC protein overexpression, MYC rearrangement, high proliferative activity, light-chain restriction, and loss of conventional B-cell markers can occur in both categories and should not be used as stand-alone discriminators. When evidence does not converge, reports should state the findings favoring each category, identify unresolved conflicts, and recommend the next diagnostic steps. This framework remains to be validated in independent cohorts.